Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium.NAPA, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Senetek PLC (BULLETIN BOARD: SNKTY) , a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Mark Nestor presented on Pyratine-6(TM) at the 6th Annual South Beach Symposium in Miami.
In his presentation to leading dermatologists at the Symposium, Dr. Nestor outlined the attributes of Pyratine-6(TM) for the treatment of photodamaged skin as demonstrated in clinical trial results. Pyratine-6(TM) achieved significant improvement in skin roughness, increased skin moisture content and reduced erythema erythema (ĕr'əthē`mə), more or less diffuse redness of the skin due to concentration of an abnormally large amount of blood within the small vessels of the skin (hyperemia), as in burns. (redness due to capillary congestion The condition of a network when there is not enough bandwidth to support the current traffic load.
congestion - When the offered load of a data communication path exceeds the capacity. ) in as early as two weeks. In addition, Pyratine-6(TM) was shown to reduce mottled hyperpigmentation Hyperpigmentation Definition
Hyperpigmentation is the increase in the natural color of the skin.
Melanin, a brown pigment manufactured by certain cells in the skin called melanocytes, is responsible for skin color. and fine wrinkles and was well tolerated by patients, with none of the skin irritation reported for retinoids and alpha hydroxyl acids. Based on positive results demonstrated in clinical evaluations, Pyratine-6(TM) is currently in clinical trials for the treatment of acne rosacea.
Mark S. Nestor, MD, PhD is a Clinical Associate Professor of the Department of Dermatology and Cutaneous cutaneous /cu·ta·ne·ous/ (ku-ta´ne-us) pertaining to the skin.
Of, relating to, or affecting the skin.
Pertaining to the skin. Surgery at the University of Miami This article is about the university in Coral Gables, Florida. For the university in Oxford, Ohio, see Miami University.
The University of Miami (also known as Miami of Florida, UM, or just The U Miller School of Medicine. He serves as Director of the Center for Cosmetic Enhancement and Director of the Center for Clinical and Cosmetic Studies in Aventura, Florida. In addition, Dr. Nestor is Co-Chairman of the Board of Directors of Advanced Dermatology Management, a physician practice management company, and is currently the immediate past President of the International Society for Cosmetic and Laser Surgeons. He is the President of the American Society for Photodynamic Therapy and a Past President of the Florida Society of Dermatology and Dermatologic Surgery. Dr. Nestor is recognized as a world expert in cutaneous laser surgery, photodynamic therapy as well as the use of fillers and toxins in aesthetic medicine.
Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "Pyratine-6(TM) has been well received by the dermatological community, and we are pleased that the compound is soon to complete additional clinical evaluation for the treatment of acne rosacea, a chronic dermatosis dermatosis /der·ma·to·sis/ (der?mah-to´sis) pl. dermato´ses any skin disease, especially one not characterized by inflammation. afflicting more than 45 million people worldwide."
About Senetek PLC
Senetek PLC (BULLETIN BOARD: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.
For more information, visit the company's website at http://www.senetekplc.com/.
This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and . Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
CONTACT: Marjorie Hays, Vice President, Communications of Senetek PLC, +1-707-226-3900, ext. 102
Web site: http://www.senetekplc.com/